2'-(3-(4-(4-chlorophenyl)piperazin-1-yl)propyl)-7',8'-dihydro-3'H-spiro[cyclopropane-1,6'-quinazolin]-4'(5'H)-one | 1536109-83-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2'-(3-(4-(4-chlorophenyl)piperazin-1-yl)propyl)-7',8'-dihydro-3'H-spiro[cyclopropane-1,6'-quinazolin]-4'(5'H)-one
• 英文别名: 2-[3-[4-(4-chlorophenyl)piperazin-1-yl]propyl]spiro[3,5,7,8-tetrahydroquinazoline-6,1'-cyclopropane]-4-one
• CAS: 1536109-83-7
• 化学式: C₂₃H₂₉ClN₄O
• 分子量: 412.962
• InChiKey: TXJIZRWOMFSPJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.45
• 重原子数：
  29.0
• 可旋转键数：
  5.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  52.23
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  螺[2.5]-6-辛酮 在 乙醇 、 sodium 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 2'-(3-(4-(4-chlorophenyl)piperazin-1-yl)propyl)-7',8'-dihydro-3'H-spiro[cyclopropane-1,6'-quinazolin]-4'(5'H)-one
  参考文献：
  名称：

  Tetrahydroquinazolinone Derivatives as PARP Inhibitors

  摘要：

  公开了式（I）的化合物，其互变异构体、立体异构体和其药学上可接受的盐，其中R1-R6、R7a-d、R8a-d、A、M、n和p如规范中所定义，包括一种化合物、互变异构体、立体异构体或其盐的药物组合物，以及治疗或预防疾病或紊乱的方法，例如癌症，这些疾病或紊乱可通过抑制受试者的PARP酶来治疗或预防。

  公开号：

  US20150152118A1

文献信息

• [EN] TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS<br/>[FR] DÉRIVÉS TÉTRAHYDROQUINAZOLINONE UTILISÉS COMME INHIBITEURS DE PARP
  申请人：LUPIN LTD

  公开号：WO2014009872A1

  公开（公告）日：2014-01-16

  Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

  公开的是式(I)的化合物，它们的互变异构体、立体异构体和药学上可接受的盐，其中R1-R6、R7a-d、R8a-d、A、M、n和p如规范中所定义，包括一种化合物、互变异构体、立体异构体或其盐的药物组合物，以及治疗或预防疾病或疾病的方法，例如癌症，通过抑制受试者的PARP酶可治疗或预防的疾病。
• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF 1-ARYL 2-AMINOMETHYL CYCLOPROPANE CARBOXYAMIDE (Z) DERIVATIVES, THEIR ISOMERS AND SALTS<br/>[FR] PROCÉDÉ PERFECTIONNÉ POUR LA PRÉPARATION DE DÉRIVÉS DE 1-ARYL-2-AMINOMÉTHYLCYCLOPROPANECARBOXAMIDE (Z), DE LEURS ISOMÈRES ET DE LEURS SELS
  申请人：MICRO LABS LTD

  公开号：WO2014009767A1

  公开（公告）日：2014-01-16

  The present invention relates to an improved and one-pot process for the preparation of 1-Aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers of formula (I) or its pharmaceutically acceptable salt thereof wherein R1 and R2 are represents independently selected from the group consisting of hydrogen, lower alkyl, lower aryl, and lower-alkylaryl, which aryl or alkylaryl group is optionally substituted by a halogen atom.

  本发明涉及一种改进的单锅法制备1-芳基2-氨甲基环丙烷羧酰胺（z）衍生物及其异构体的过程，其化学式为（I）或其药学上可接受的盐，其中R1和R2分别代表从氢、低烷基、低芳基和低烷基芳基中独立选择的基团，所述芳基或烷基芳基基团可选择性地被卤原子取代。
• Tetrahydroquinazolinone derivatives as PARP inhibitors
  申请人：Lupin Limited

  公开号：US09359367B2

  公开（公告）日：2016-06-07

  Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

  本发明涉及式（I）的化合物、其互变异构体、立体异构体和其药学上可接受的盐，其中R1-R6，R7a-d，R8a-d，A，M，n和p如规范中所定义，所述药物组合物包括该化合物、互变异构体、立体异构体或其盐，以及治疗或预防疾病或疾病的方法，例如癌症，该疾病可以通过抑制受体PARP酶来进行治疗或预防。
• TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS
  申请人：Lupin Limited

  公开号：EP2870140A1

  公开（公告）日：2015-05-13
• USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20180071244A1

  公开（公告）日：2018-03-15

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.